title: Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer.
abstract: OBJECTIVE
  The study aimed to investigate the effect of high dose radioactive iodine (RAI) on parathyroid function in patients with differentiated thyroid cancer.
  
  
  METHODS
  Nineteen patients (8 men/11 women, age 46.5 +/- 13.2 years) undergoing RAI for thyroid remnant ablation were enrolled in the study. The biochemical parameters related to parathyroid function [serum calcium (Ca), phosphate (P), creatinine (Cr), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), urinary Ca, cAMP concentrations and the maximum tubular capacity for phosphate per unit volume of glomerular filtrate (TmP/GFR)] were evaluated at baseline and at the 1st, 3rd, 6th and 12th months of RAI administration. SPSS 15.0 was used for statistical analysis.
  
  
  RESULTS
  For all patients, thyroid-stimulating hormone levels were >30 U/ml at baseline and <0.1 U/ml at the following visits. Serum iPTH levels were decreased significantly at the 6th month and reached basal levels at the 12th month (baseline vs. 6th p = 0.027, 1st vs. 6th p = 0.011, 3rd vs. 6th p = 0.047, 3rd vs. 12th p = 0.014, 6th vs. 12th p = 0.001). At the 6th month, P and TmP/GFR levels were higher (p = 0.036, 0.017, respectively), and urinary cAMP measurements were lower (p = 0.020) compared to those of the 1st month. No difference was detected concerning the other parameters. Serum Ca levels decreased below 2.1 mmol/l in several patients (n = 5 at 1st month, n = 4 at 3rd month, n = 8 at 6th month and n = 3 at 12th month) without clinical symptoms.
  
  
  CONCLUSIONS
  The study indicated a transient decline in PTH levels at the 6th month following RAI therapy. Although this decrease did not cause symptoms in any of the present cases, this pattern might be important especially in individuals with diminished parathyroid background.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Millet cad., Capa, Istanbul, Turkey.
authors.forename: Aytekin
authors.initials: A
authors.lastname: Guven
authors.forename: Serpil
authors.initials: S
authors.lastname: Salman
authors.forename: Harika
authors.initials: H
authors.lastname: Boztepe
authors.forename: Sema
authors.initials: S
authors.lastname: Yarman
authors.forename: Refik
authors.initials: R
authors.lastname: Tanakol
authors.forename: Halil
authors.initials: H
authors.lastname: Azizlerli
authors.forename: Faruk
authors.initials: F
authors.lastname: Alagol
mesh_terms: D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010280:Parathyroid Glands / Q000378:metabolism / Q000503:physiopathology* / Q000528:radiation effects*; D010281:Parathyroid Hormone / Q000097:blood; D011829:Radiation Dosage; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D013964:Thyroid Neoplasms / Q000097:blood / Q000532:radiotherapy*; D013997:Time Factors
chemical_list: D007457:Iodine Radioisotopes; D010281:Parathyroid Hormone; D002118:Calcium